Symbols

QGEN

Qiagen·NYSE

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

Bullish Abandoned Baby

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About QGEN

Qiagen N.V.

A leading provider of molecular diagnostics and sample preparation technologies for life sciences and molecular diagnostics markets

Industry

Life Science Tools and Services

Established Date

Listing Date

01/10/2018

Exchange

New York Stock Exchange

Full-time Employees

5,654

Fiscal Year Ends

12-31

Website

www.qiagen.com

Security Type

Common stock

Office address

Hulsterweg 82, 5912 PL Venlo, The Netherlands

Business

Introduction

Qiagen N.V. is a Dutch holding company whose subsidiary is the main provider of Sample and Assay Technologies. The company is a global leader in "sample to insight" solutions, serving more than 500,000 clients across two broad customer bases: Molecular Diagnostics (Human Healthcare) and Life Sciences (Academia, Pharma R&D and Industrial Applications, primarily Forensic Medicine). The company operates its products in more than 100 countries.

Company Financials

EPS

QGEN has released its 2025 Q4 earnings. EPS was reported at 0.62, versus the expected 0.62, meeting expectations. The chart below visualizes how QGEN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

QGEN has released its 2025 Q4 earnings report, with revenue of 540.42M, reflecting a YoY change of 3.69%, and net profit of 107.83M, showing a YoY change of 22.09%. The Sankey diagram below clearly presents QGEN's revenue sources and cost distribution.